

Solutions Corp (S3), Bethesda, MD; Glover 38th Street Holdings LLC, Smithfield, VA; KAB Laboratories, Inc., San Diego, CA; Tektronix, Inc., Beaverton, OR; ORSA Technologies, LLC, Sierra Vista, AZ; DEEPSIG, Inc., Arlington, VA; QRC Technologies, Fredericksburg, VA; Freedom Technologies, Inc., Arlington, VA; Gigatronics, Incorporated, Dublin, CA; Cambium Networks, Inc., Rolling Meadows, IL; Epiq Solutions, Schaumburg, IL; LinQuest Corporation, Los Angeles, CA; Syncopated Engineering, Inc., Ellicott City, MD; Bascom Hunter Technologies, Inc., Baton Rouge, LA; InCadence Strategic Solutions, Manassas, VA; and Long Wave, Inc., Oklahoma City, OK, have been added as parties to this venture.

Also, Hercules Research LLC, Chantilly, VA, has withdrawn from this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NSC intends to file additional written notifications disclosing all changes in membership.

On May 24, 2014, NSC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on November 4, 2014 (72 FR 65424).

The last notification was filed with the Department on April 10, 2017. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on May 12, 2017 (82 FR 22160).

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust Division.*

[FR Doc. 2017-17148 Filed 8-14-17; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Antitrust Division

#### Notice Pursuant to the National Cooperative Research and Production Act of 1993—Network Centric Operations Industry Consortium, Inc.

Notice is hereby given that, on July 11, 2017, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Network Centric Operations Industry Consortium, Inc. (“NCOIC”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the

Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Lewis Combs (individual member), Cincinnati, OH, has been added as a party to this venture.

Also, Tata Power SED, Mumbai, INDIA; and beamSmart, Vienna, VA, have withdrawn as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and NCOIC intends to file additional written notifications disclosing all changes in membership.

On November 19, 2004, NCOIC filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on February 2, 2005 (70 FR 5486).

The last notification was filed with the Department on March 13, 2017. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on April 4, 2017 (82 FR 16420).

**Patricia A. Brink,**

*Director of Civil Enforcement, Antitrust Division.*

[FR Doc. 2017-17150 Filed 8-14-17; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

#### Raman I. Popli, M.D.; Decision and Order

On May 4, 2017, the Assistant Administrator, Diversion Control Division, Drug Enforcement Administration (hereinafter, DEA or Government), issued an Order to Show Cause to Raman Popli, M.D. (hereinafter, Registrant) of McHenry, Illinois, the holder of Certificate of Registration No. BP7189067. GX 2 (Registration Certificate). The Show Cause Order proposed the revocation of Registrant’s Certificate of Registration on the ground that Registrant does “not have authority to handle controlled substances in the State of Illinois,” the State in which he is registered. GX 1, at 1 (citing 21 U.S.C. 823(f) and 824(a)(3)).

As the jurisdictional basis for the proceeding, the Show Cause Order alleged that registration BP7189067, pursuant to which Registrant is authorized to prescribe controlled substances in Schedules II through V, expires on March 31, 2019. *Id.*

As the substantive grounds for the proceeding, the Show Cause Order alleged that Registrant currently lacks “authority to handle controlled substances in the State of Illinois.” *Id.* It alleged that, on March 13, 2017, Illinois suspended Registrant’s “authority to prescribe and administer controlled substances.” *Id.*

The Show Cause Order notified Registrant of his right to request a hearing on the allegation or to submit a written statement while waiving his right to a hearing, the procedures for electing each option, and the consequences for failing to elect either option. *Id.* at 2, citing 21 CFR 1301.43. The Show Cause Order also notified Registrant of the opportunity to submit a corrective action plan. *Id.*, citing 21 U.S.C. 824(c)(2)(C).

On May 5, 2017, a DEA Office of Chief Counsel Legal Assistant faxed and mailed “via USPS First Class Mail” a copy of the Show Cause Order to Registrant’s attorney, Alan Rhine, Esq., at the fax number and business address he provided. GX 5, at 1 (Legal Assistant Declaration dated June 8, 2017) and attachment. The Legal Assistant’s Declaration appended emails to and from Registrant’s attorney confirming that Registrant authorized him to accept service of documents from the DEA on Registrant’s behalf. *Id.* I find that the Government’s service of the Show Cause Order on Registrant was legally sufficient.

The Government submitted a Request for Final Agency Action (hereinafter, RFAA) dated June 9, 2017 and an evidentiary record to support the Show Cause Order’s allegations. According to the Government’s representations in the RFAA, “more than thirty days have passed since the Order to Show Cause was served on Respondent and no request for hearing has been received by DEA, and . . . no written statement or other correspondence has been filed in lieu of a hearing request.” RFAA, at 1.

Based on the Government’s representations and my review of the record, I find that more than 30 days have now passed since the date of service of the Show Cause Order on Registrant through his attorney, and that neither Registrant, his attorney, nor anyone else purporting to represent him, has requested a hearing or submitted a written statement while waiving his right to a hearing. Accordingly, I find that Registrant has waived his right to a hearing and his right to submit a written statement. 21 CFR 1301.43(d). I therefore issue this Decision and Order based on the record submitted by the Government. 21 CFR 1301.43(e).

## Findings of Fact

### Registrant's DEA Registration

Registrant currently holds DEA practitioner registration BP7189067 authorizing him to dispense controlled substances in Schedules II through V. GX 2. This registration expires on March 31, 2019. *Id.*

DEA practitioner registration BP7189067 is assigned to Registrant at "Dr Raman Popli and Associates, Ltd, 5415 Bull Valley Road, McHenry, IL 60050." *Id.*

### The Status of Registrant's State Licenses

On March 13, 2017, the Director of the Division of Professional Regulation of the Illinois Department of Financial and Professional Regulation issued an Order suspending Registrant's Illinois Physician and Surgeon License No. 036-104035 and Illinois Controlled Substance License No. 336-064820 pending proceedings before an Administrative Law Judge at the Department of Financial and Professional Regulation and the Medical Disciplinary Board of the State of Illinois. GX 3 (Order, at 1-2).<sup>1</sup> According to the Order, "the public interest, safety and welfare imperatively require emergency action to prevent the continued practice of Raman Popli, M.D., Respondent, in that Respondent's actions constitute an immediate danger to the public." *Id.* (Order, at 1).

## Discussion

Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized to suspend or revoke a registration issued under section 823 of the Controlled Substances Act (hereinafter, CSA), "upon a finding that the registrant . . . has had his State License . . . suspended [or] . . . revoked by competent State authority and is no longer authorized by State law to engage in the . . . dispensing of controlled substances." With respect to a practitioner, the DEA has also long held that the possession of authority to dispense controlled substances under the laws of the State in which a practitioner engages in professional practice is a fundamental condition for obtaining and maintaining a practitioner's registration. *See, e.g., James L. Hooper*, 76 FR 71,371 (2011), *pet. for rev. denied*, 481 Fed. Appx. 826 (4th Cir. 2012); *Frederick Marsh Blanton*, 43 FR 27,616 (1978).

This rule derives from the text of two provisions of the CSA. First, Congress

defined the term "'practitioner' [to] mean[ ] a . . . physician, dentist, . . . or other person licensed, registered, or otherwise permitted, by . . . the jurisdiction in which he practices . . . , to distribute, dispense, [or] administer . . . a controlled substance in the course of professional practice . . . ." 21 U.S.C. 801(21). Second, in setting the requirements for obtaining a practitioner's registration, Congress directed that "[t]he Attorney General shall register practitioners . . . if the applicant is authorized to dispense . . . controlled substances under the laws of the State in which he practices." 21 U.S.C. 823(f). Because Congress has clearly mandated that a practitioner possess state authority in order to be deemed a practitioner under the CSA, the DEA has held repeatedly that revocation of a practitioner's registration is the appropriate sanction whenever he is no longer authorized to dispense controlled substances under the laws of the State in which he practices. *See, e.g., Hooper*, 76 FR at 71,371-72; *Sheran Arden Yeates*, 71 FR 39,130, 39,131 (2006); *Dominick A. Ricci*, 58 FR 51,104, 51,105 (1993); *Bobby Watts*, 53 FR 11,919, 11,920 (1988); *Blanton*, 43 FR at 27,616.

Under Illinois law, "[n]o person shall practice medicine . . . without a valid, active license to do so . . . ." 225 ILCS 60/3 (2017). Further, "[e]very person who . . . dispenses any controlled substances . . . must obtain a registration issued by the [Illinois] Department of Financial and Professional Regulation in accordance with its rules." 720 ILCS 570/302(a).

In this case, the Division of Professional Regulation of the Illinois Department of Financial and Professional Regulation took emergency action to suspend Registrant's Physician and Surgeon License and Illinois Controlled Substance License. *Supra*. Consequently, Registrant is not currently authorized to handle controlled substances in the State of Illinois, the State in which he is registered, and he is not entitled to maintain his registration. *Blanton, supra*. Accordingly, I will order this his registration be revoked and that any pending application for the renewal or modification of his registration be denied. 21 U.S.C. 824(a)(3) and 823(f).

## Order

Pursuant to the authority vested in me by 21 U.S.C. 824(a), as well as 28 CFR 0.100(b), I order that DEA Certificate of Registration BP7189067 issued to Raman I. Popli, M.D., as well as DATA-Waiver Identification No. XP7189067, be, and they hereby are, revoked. I

further order that any pending application of Raman I. Popli, M.D., to renew or modify this registration, as well as any other pending application by him for registration in the State of Illinois, be, and it hereby is, denied. This order is effective immediately.<sup>2</sup>

Dated: August 4, 2017.

**Chuck Rosenberg,**  
Acting Administrator.

[FR Doc. 2017-17146 Filed 8-14-17; 8:45 am]

BILLING CODE 4410-09-P

## LEGAL SERVICES CORPORATION

### Sunshine Act Meeting Notice

**DATE AND TIME:** The Legal Services Corporation's Finance Committee will meet telephonically on August 21, 2017. The meeting will commence at 12:00 p.m., EDT, and will continue until the conclusion of the Committee's agenda.

**LOCATION:** John N. Erlenborn Conference Room, Legal Services Corporation Headquarters, 3333 K Street NW., Washington, DC 20007.

**PUBLIC OBSERVATION:** Members of the public who are unable to attend in person but wish to listen to the public proceedings may do so by following the telephone call-in directions provided below.

### CALL-IN DIRECTIONS FOR OPEN SESSIONS:

- Call toll-free number: 1-866-451-4981;

- When prompted, enter the following numeric pass code: 5907707348;

- When connected to the call, please immediately "MUTE" your telephone.

Members of the public are asked to keep their telephones muted to eliminate background noises. To avoid disrupting the meeting, please refrain from placing the call on hold if doing so will trigger recorded music or other sound. From time to time, the Chair may solicit comments from the public.

**STATUS OF MEETING:** Open.

### MATTERS TO BE CONSIDERED:

1. Approval of agenda
2. Approval of minutes of the Committee's Open Session telephonic meeting of June 21, 2017
3. Approval of minutes of the Committee's Open Session telephonic meeting of June 26, 2017

<sup>1</sup> Since the pages in GX 3 are not consecutively paginated, this Decision and Order identifies the relevant document in GX 3 and the relevant page number of that document.

<sup>2</sup> For the same reasons the Division of Professional Regulation of the Illinois Department of Financial and Professional Regulation suspended Registrant's Illinois Physician and Surgeon License and Illinois Controlled Substance License, I find that the public interest necessitates that this Order be effective immediately. 21 CFR 1316.67.